
FDA shuts two eateries, ice factory over hygiene violations
Panaji:
The directorate of food and drugs administration (FDA) closed two eateries in Assagao for operating in unhygienic conditions. The first one sold momos, and the other sold biryani.
Tired of too many ads? go ad free now
Janta Ice Factory at Assagao, operating without an FDA licence, was directed to suspend operations and other premises were issued improvement notices.
During the inspection, the FDA fined Ms Zaiqua Rs 10,000 and Ms Bobby Fast Food Rs 8,000 operating at Alankar, Mapusa, for violating norms under the Food Safety Act 2006. The FDA found most premises compliant with norms at Alankar.
The inspection team, led by FDA director Shweta Dessai, included designated officer North Goa Richard Noronha, Rajaram Patil, Amit Mandrekar, Nousin Mulla, and Sneha Gaude.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
an hour ago
- Time of India
Study finds Ozempic is linked to severe eye bleeding disorder in patients; experts share risk factors
A shocking study conducted in Israel has found that patients who take Ozempic or similar weight-loss drugs face a potential blinding condition due to internal bleeding in the eyes. According to the Daily Mail, patients who take the weight-loss shots were twice as likely to suffer from a serious degenerative eye disease as compared to those who do not take them. The particular condition is called neovascular age-related macular degeneration (nAMD), which mostly causes leaky blood vessels to grow behind the eye. This can even spill fluid into the retina, leading to permanent damage and blindness in the future. But is Ozempic really linked to bleeding of the eyes? Ozempic (semaglutide) is a medication prescribed to treat type 2 diabetes and help with weight loss. "Although it has been proven to have remarkable effects in regulating blood sugar and facilitating weight loss, it also comes with various issues and possible side effects," says Dr. Bhumesh Tyagi, Senior Consultant, Internal Medicine, Sharda Hospital. On the other hand, "Nausea, vomiting, diarrhoea, and constipation are the usual side effects. Serious complications can include pancreatitis, kidney, and gallbladder problems," adds Dr. Tyagi. Others have reported the risk of thyroid tumours, but this has been seen largely in animal studies. While the exact link between weight-loss drugs and vision problems isn't known, scientists believe that they bind to GLP-1 receptors in the eye, triggering the growth of the blood vessels. However, the cases were rare, but experts warned of the concerning signal in the data, saying that further research is needed to confirm the condition. FDA approved Ozempic to lower kidney disease in type 2 diabetics On the other hand, a few months ago, the FDA approved Ozempic to lower kidney disease in type 2 diabetes patients. "Chronic kidney disease (CKD) affects between 30 to 40 per cent of individuals living with type 2 diabetes in India, making it one of the most common and serious complications associated with the condition," says Dr. Rajiv Kovil, Head of Diabetology, Zandra Healthcare & Co-founder, Rang De Neela Initiative. Across the globe, including in India, diabetes-related complications are heavily linked to both cardiovascular and kidney disorders.


Time of India
a day ago
- Time of India
FDA shuts 3 food businesses at Patradevi, Margao
Panaji: The food and drugs administration (FDA) directed two food business operators—a restaurant and a cashew shop—to suspend operations at Patradevi, Pernem, due to unhygienic conditions. The FDA inspected 18 outlets at Patradevi, issued improvement notices, and gave them 14 days to comply. They seized Rs 50,000 worth of food items, including chips, chocolates, and dry fruits with artificial colours. Samples of sweets were also taken for testing. The FDA also directed a restaurant in Margao to shut down for failing to pay a fine and for non-compliance with FDA directions following its inspection on April 28. They found that only 5 of 30 deficiencies were addressed and ordered the food operator to stop all activities and submit a compliance report. Get the latest lifestyle updates on Times of India, along with Eid wishes , messages , and quotes !


Hans India
a day ago
- Hans India
Alzheimer's gene therapy shows promise to prevent brain damage
New Delhi: A novel gene therapy for Alzheimer's disease, which showed promise to protect the brain from damage and preserve cognitive function, has renewed hope for millions of patients with the neurodegenerative disease. Worldwide, approximately 57 million people live with dementia, and Alzheimer's disease is the most common cause, accounting for 60-70 per cent of cases. Alzheimer's occurs when abnormal proteins build up in the brain, leading to the death of brain cells and declines in cognitive function and memory. While current treatments can manage symptoms of Alzheimer's, the new gene therapy aims to halt or even reverse disease progression, said researchers from the University of California San Diego School of Medicine. They noted that, unlike existing treatments for Alzheimer's that target unhealthy protein deposits in the brain, the new approach could help address the root cause of Alzheimer's disease by influencing the behaviour of brain cells themselves. The study investigated the effect of hippocampal SynCav1 delivery in two distinct preclinical mice models. The results, published in the journal Signal Transduction and Targeted Therapy, showed that delivering the treatment at the symptomatic stage of the disease preserved hippocampal-dependent memory -- a critical aspect of cognitive function that is often impaired in Alzheimer's patients. Further, the finding stated that compared to healthy mice of the same age, the treated mice also had a similar pattern of gene expression. This suggests that the treatment has the potential to alter the behaviour of diseased cells to restore them to a healthier state. 'While multiple newly FDA-approved treatments focus on targeting amyloid-beta clearance in Alzheimer's patients, the therapeutic value of SynCav1 lies in its ability to protect vulnerable neurons and augment cellular responses -- mechanisms that differ from currently approved therapies,' said the researchers in the paper. Due to the multitude of neurotoxicity in the Alzheimer's brain, the team called for further studies to investigate SynCav1's therapeutic role when combined with amyloid-targeted drugs to enhance clinical outcomes.